JFL Life
NSE: JFLLIFE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock JFL Life's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
JFL Life Sciences Ltd is a WHO-GMP certified pharmaceutical company incorporated in 2010. The firm specialises in the manufacturing and marketing of dry powder injectable and solid oral dosage forms, including beta-lactam and general pharmaceutical products.
Business Model
The company generates revenue through the production and sale of diverse pharmaceutical formulations. It leverages its manufacturing capabilities to supply products across multiple markets.
- Certification:WHO-GMP
Growth Outlook
Growth is expected to be driven by the company's focus on expanding its portfolio of injectable and oral dosage formulations. Continued adherence to international quality standards supports its market positioning.
Key Risks
- Regulatory Compliance. Failure to maintain WHO-GMP certifications could lead to the suspension of manufacturing operations or loss of market access.
- Price Controls. The Indian pharmaceutical sector is subject to government-mandated price caps on essential medicines, which may impact profit margins.
- Input Cost Volatility. Fluctuations in the cost of Active Pharmaceutical Ingredients (APIs) and raw materials can adversely affect the company's operating profitability.
- Competitive Intensity. The company faces significant competition from both large-scale domestic players and international firms within the generic drug market.
Start your research today
Unlock AI insights, financials, peers and live data on JFL Life and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
JFL LifeJFLLIFE | ₹66 Cr | — | — | — | 9.0% | — | — | -22.8% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Mar 2026
Financials
JFL Life
NSE: JFLLIFE · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock JFL Life's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
JFL Life Sciences Ltd is a WHO-GMP certified pharmaceutical company incorporated in 2010. The firm specialises in the manufacturing and marketing of dry powder injectable and solid oral dosage forms, including beta-lactam and general pharmaceutical products.
Business Model
The company generates revenue through the production and sale of diverse pharmaceutical formulations. It leverages its manufacturing capabilities to supply products across multiple markets.
- Certification:WHO-GMP
Growth Outlook
Growth is expected to be driven by the company's focus on expanding its portfolio of injectable and oral dosage formulations. Continued adherence to international quality standards supports its market positioning.
Key Risks
- Regulatory Compliance. Failure to maintain WHO-GMP certifications could lead to the suspension of manufacturing operations or loss of market access.
- Price Controls. The Indian pharmaceutical sector is subject to government-mandated price caps on essential medicines, which may impact profit margins.
- Input Cost Volatility. Fluctuations in the cost of Active Pharmaceutical Ingredients (APIs) and raw materials can adversely affect the company's operating profitability.
- Competitive Intensity. The company faces significant competition from both large-scale domestic players and international firms within the generic drug market.
Start your research today
Unlock AI insights, financials, peers and live data on JFL Life and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026